Fayetteville drug development startup BiologicsMD announced on Tuesday a partnership with an Oklahoma firm that will make the company’s osteoporosis treatment. BioMD, which has developed what it considers a breakthrough treatment for the disease called PTH-CBD, has contracted with Cytovance Biologics of Oklahoma City to develop a manufacturing platform for the drug. In addition, the firm has welcomed its newest board member, Ensysce Biosciences CEO Lynn Kirkpatrick, to help guide it through the Food and Drug Administration approval process. “We are excited to announce our partnership with Cytovance to develop the manufacturing platform for our PTH-CBD treatment,” BioMD President Paul Mlakar said in a news release. “Their expertise will play a key role in accelerating the development of this compound that will hopefully improve the lives of the millions of individuals who suffer from osteoporosis.” Click here to read the full article from Arkansas Business: BiologicsMD Signs Deal to Make Its Osteoporosis Treatment
Footer
